14Nov 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA‐HF

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA‐HF

Among patients with heart failure and reduced ejection fraction (HFrEF), those with atrial fibrillation (AF) may respond differently to certain treatments than patients without AF. We investigated the efficacy and safety of dapagliflozin in patients with HFrEF with and without AF in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure trial (DAPA‐HF). We also examined the effect of dapagliflozin on new‐onset AF. The primary outcome was the composite of an episode of worsening HF (HF hospitalization or urgent HF visit requiring intravenous therapy) or cardiovascular death. Of the 4744 patients randomized, 1910 (40.3%) had “any AF” (history of AF or AF on enrolment electrocardiogram). Compared with placebo, dapagliflozin reduced the risk of worsening HF or cardiovascular death to a similar extent in patients with and without any AF...

  • #cardiology

Like

Save

Share